ImmCelz

Creative Medical Technology (CELZ) secured USPTO patent allowance through 2040 for its ImmCelz™ therapy targeting heart failure and post-heart attack damage. The treatment, delivered via minimally invasive outpatient procedure, addresses a potential US patient population exceeding 11 million. While this significantly broadens the company’s regenerative medicine IP portfolio, the therapy remains in development and lacks FDA approval or current revenue.